Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Genprex ( (GNPX) ) has provided an announcement.
On April 30, 2026, Genprex announced that the Israel Patent Office granted a patent covering the use of its Reqorsa Gene Therapy in combination with PD-1 antibodies for the treatment of cancer. This new protection adds to previously granted Reqorsa combination patents in major markets including the U.S., Japan, China and Europe, strengthening the company’s global IP position in oncology.
The company framed the Israeli patent as a strategic expansion that supports its development of Reqorsa with established cancer drugs for lung cancer patients. The announcement highlighted Israel’s rising lung cancer burden and high mortality rates, underscoring the commercial and clinical relevance of securing patent coverage in that market for Genprex’s future operations and stakeholder interests.
More about Genprex
Genprex, Inc. is a biotechnology company developing gene therapies for cancer and diabetes, with a key focus on its lead candidate Reqorsa Gene Therapy (quaratusugene ozeplasmid). Reqorsa is initially being developed in combination with approved cancer drugs and immunotherapies to treat lung cancer, targeting markets worldwide where the company has been building an extensive intellectual property portfolio.
Average Trading Volume: 908,343
Technical Sentiment Signal: Sell
Current Market Cap: $8.01M
For an in-depth examination of GNPX stock, go to TipRanks’ Overview page.